Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J. clin. sleep med ; 11(10)Oct. 2015. ilus, tab
Artigo em Inglês | BIGG | ID: biblio-964516

RESUMO

A systematic literature review and meta-analyses (where appropriate) were performed and the GRADE approach was used to update the previous American Academy of Sleep Medicine Practice Parameters on the treatment of intrinsic circadian rhythm sleep-wake disorders. Available data allowed for positive endorsement (at a second-tier degree of confidence) of strategically timed melatonin (for the treatment of DSWPD, blind adults with N24SWD, and children/ adolescents with ISWRD and comorbid neurological disorders), and light therapy with or without accompanying behavioral interventions (adults with ASWPD, children/adolescents with DSWPD, and elderly with dementia). Recommendations against the use of melatonin and discrete sleep-promoting medications are provided for demented elderly patients, at a second- and first-tier degree of confidence, respectively. No recommendations were provided for remaining treatments/ populations, due to either insufficient or absent data. Areas where further research is needed are discussed.


Assuntos
Humanos , Criança , Adolescente , Adulto , Transtornos do Sono-Vigília/tratamento farmacológico , Fototerapia/métodos , Transtornos Intrínsecos do Sono/tratamento farmacológico , Transtornos do Despertar do Sono/tratamento farmacológico , Transtornos da Transição Sono-Vigília/tratamento farmacológico , Abordagem GRADE , Melatonina/uso terapêutico
2.
Trop Doct ; 29(3): 148-51, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10448237

RESUMO

Of 68 patients who were admitted with acute quadriparesis to a hospital in northern India, over 70% were found to be hypokalaemic. The most common cause of hypokalaemia was that associated with gastroenteritis (54%). These patients had all received intravenous fluids previously. It is likely that their hypokalaemia was caused by gastrointestinal loss compounded by parenteral fluid replacement. The next most common group of hypokalaemia-associated quadriparesis had no obvious cause for hypokalaemia (38%). Hypokalaemia-induced quadriparesis is a potentially life-threatening illness which can be readily treated with potassium supplements. The physician should consider hypokalaemia in patients who present with acute onset quadriparesis, and even if diagnostic tests for hypokalaemia are not available, should consider a judicious trial of potassium supplementation empirically, provided that there are no contraindications.


Assuntos
Hipopotassemia/complicações , Paresia/etiologia , Quadriplegia/etiologia , Doença Aguda , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Humanos , Hipopotassemia/diagnóstico , Hipopotassemia/epidemiologia , Índia/epidemiologia , Lactente , Masculino , Pessoa de Meia-Idade , Nepal/epidemiologia
3.
Mutagenesis ; 14(4): 351-6, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10390501

RESUMO

A bacterial plasmid was constructed on which the regulatory region of the umuC gene of Escherichia coli was fused to the coding sequence of the green fluorescent protein gene (gfp) from the jellyfish Aequorea victoria. Escherichia coli AB1157 strains carrying the plasmid emitted fluorescence in the presence of mutagens that induce the SOS DNA repair system. Data on tests with nitrosoguanidine, methylmethane sulphonate and UV radiation (254 nm) are presented. Although fluorescent detection using this system was not as rapid or sensitive as a similar luminescent equivalent (umuC-luxAB), the gfp reporter system was more robust. Escherichia coli umu gene induction was also analysed in Salmonella typhimurium TA1537 cells following plasmid transfer and exposure to the same range of mutagens. There was no significant difference in sensitivity between the two species. These preliminary results will provide the basis for development of mutagenicity test systems useful in the testing of complex mixtures, such as environmental samples, and the investigation of physiological parameters influencing spontaneous mutagenesis in bacteria.


Assuntos
Bactérias/genética , Proteínas de Bactérias/genética , Proteínas de Escherichia coli , Genes Reporter/genética , Luciferases/química , Proteínas Luminescentes/química , Testes de Mutagenicidade/métodos , Resposta SOS em Genética/genética , Animais , Fusão Gênica Artificial , Bactérias/efeitos dos fármacos , Bactérias/crescimento & desenvolvimento , Bactérias/efeitos da radiação , DNA Polimerase Dirigida por DNA , Escherichia coli/genética , Fluorescência , Genes Reporter/efeitos dos fármacos , Genes Reporter/efeitos da radiação , Proteínas de Fluorescência Verde , Luciferases/genética , Medições Luminescentes , Proteínas Luminescentes/genética , Metanossulfonato de Metila/toxicidade , Mutagênicos/toxicidade , Nitrosoguanidinas/toxicidade , Resposta SOS em Genética/efeitos dos fármacos , Resposta SOS em Genética/efeitos da radiação , Salmonella typhimurium/genética , Cifozoários , Raios Ultravioleta/efeitos adversos
4.
Pharmacology ; 49(1): 23-32, 1994 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8090835

RESUMO

It is well known that beta-adrenergic receptors will down-regulate in the presence of high circulating levels of beta-adrenergic agonists over extended periods of time. However, less is known with respect to the effect of Ca2+ channel antagonist on their receptors. The purpose of this study was to determine if chronic administration of high dosages of verapamil (in the toxic range) could alter the density of Ca2+ channels in the heart as determined by [3H]PN 200-110 binding. A range of high verapamil concentrations was administered to rats via s.c. implantable slow-release pellets or s.c. injection. An increasing rate of mortality was observed as the dose of verapamil administered increased. Quantitation of serum verapamil concentrations demonstrated that the s.c. slow release implantable pellets were not releasing the drug evenly and instead released toxic quantities of drug during the first 24 h after implantation. Serum verapamil levels determined from verapamil-injected animals demonstrated a dose-dependent increase in circulating levels. No significant alterations in Ca2+ channel characteristics (Bmax and Kd) were noted in cardiac tissue obtained from either treatment regime. Our results demonstrate that implantable pellets are not a reliable administration method for verapamil and cardiac Ca2+ channels are unusually resistant to biochemical alterations even after administration of verapamil dosages in the toxic range.


Assuntos
Canais de Cálcio/metabolismo , Ventrículos do Coração/efeitos dos fármacos , Verapamil/administração & dosagem , Verapamil/farmacologia , Animais , Cromatografia Líquida de Alta Pressão , Preparações de Ação Retardada , Implantes de Medicamento , Feminino , Injeções Subcutâneas , Isradipino/metabolismo , Ensaio Radioligante , Ratos , Ratos Sprague-Dawley , Taxa de Sobrevida
5.
JPEN J Parenter Enteral Nutr ; 9(4): 501-3, 1985.
Artigo em Inglês | MEDLINE | ID: mdl-2863398

RESUMO

Abnormal serum liver enzymes are common in adults receiving total parenteral nutrition (TPN). The mechanism(s) responsible for these changes is unclear. One hypothesis is that there is overgrowth of intestinal anaerobic bacteria with subsequent toxic effects on the liver from endotoxins and/or bile acids. A retrospective survey of patients receiving TPN was undertaken. The patients were divided into two matched groups. One group had received metronidazole, a drug that suppresses anaerobic bacteria, while the other group had not. The administration of metronidazole during TPN was associated with prevention of the expected rise of serum alkaline phosphatase, gamma glutamyl transpeptidase, and aspartate amino-transferase. This study supports the concept that anerobic intestinal bacteria may be involved in the pathogenesis of liver changes commonly observed during TPN.


Assuntos
Hepatopatias/prevenção & controle , Metronidazol/uso terapêutico , Nutrição Parenteral Total/efeitos adversos , Nutrição Parenteral/efeitos adversos , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Doença de Crohn/terapia , Humanos , Fígado/enzimologia , Hepatopatias/enzimologia , Estudos Retrospectivos , gama-Glutamiltransferase/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA